Immunogenicity and Safety of a Chemically Synthesized Divalent Group A Streptococcal Vaccine

BACKGROUND: Group A streptococcus (GAS) infections and poststreptococcal sequelae remain a health problem worldwide, which necessitates searching for an effective vaccine, while no licensed GAS vaccine is available. We have developed a divalent peptide vaccine composed of 84 amino acids to cover the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yongxiang, Li, Suhua, Luo, Yanting, Zhao, Yunyue, Wang, Jiarui, Dong, Ruimin, Xie, Xujing, Zhu, Jieming, Liu, Jinlai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851172/
https://www.ncbi.nlm.nih.gov/pubmed/29682128
http://dx.doi.org/10.1155/2018/4702152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851172/
https://www.ncbi.nlm.nih.gov/pubmed/29682128
http://dx.doi.org/10.1155/2018/4702152

Ejemplares similares